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Fragmentary Solutions
Astex Therapeutics Puts the Pieces TogetherStumbling across a promising drug
candidate may not be mere statis-
tical probability, but more a matter
of putting the right fragments to-
gether. High throughput screening
(HTS) which combines the advan-
tages of combinatorial chemistry,
advanced computing, and robotics,
has been the mainstay of drug dis-
covery over the past 15 years or so.
Pushed by advances in analytical
methods used to identify and quan-
tify potential interactions, statistical
data analysis, and automation, HTS
is preferred over rational drug de-
sign for pharma and biotech alike.
HTS involves systematically test-
ing libraries of drug candidates
against a ‘‘target’’ protein for inhibi-
tion or activation. A basic knowledge
of the system is all that is required; it
is an unsentimental approach. HTS
is essentially a brute force process
of sorting through numbingly large
amounts of data. ‘‘In certain cases
it is the only way to do things,’’ said
Dean R. Artis, vice president, Lead
Generation, Plexxikon, Inc. ‘‘It is the
only technique that can be used for
any target class. If you can develop
an assay, you can drive an HTS
approach. That is its strength and
its weakness.’’
But despite impressive gains in
screening capacity, the number of
new drug submissions to the FDA
has not increased accordingly.
According to Joseph DiMasi, Ph.D.,
director of economic analysis at the
Tufts Center for Drug Development,
the average cost of discovery per
drug has skyrocketed and, at last
tally, averaged $802 million, with
a nonclinical contribution of $336
million, including failures (based on
year 2000 figures).
Don’t Underestimate
the Little Guys
In the same way that the tallest
fellow in a bar is the one you notice
first, HTS is biased toward com-
pounds with strong interactions.
Certain compounds that show onlyweak interactions (the shorter fel-
lows) could be overlooked.
About three years ago, fragment-
based drug discovery (FBDD) or
fragment-based screening (FBS),
an approach utilized at Abbott Lab-
oratories in the mid-1990s, started
gaining favor as a complement
to combinatorial chemistry-driven
screening efforts. After all, if every-
body is screening similar compound
libraries against fairly similar tar-
gets, the results might start looking
the same as well. ‘‘The whole gene-
sis for fragment-based drug dis-
covery conceptually came about
because [with it] you can explore
chemical spaces of very weakly in-
teracting compounds that have
much greater potential diversity,’’
said Artis.
Companies like Cam-
bridge, UK, based Astex
Therapeutics, Ltd. .
rather than looking for
a tight binding drug lead,
examine the weak inter-
actions of small frag-
ments with a target and
expand on or connect
individual fragments to
form a strongly bound
new drug candidate.
Companies like Cambridge, UK,
based Astex Therapeutics, Ltd.
(www.astex-therapeutics.com), and
its competitors Vernalis, Sunesis,
Sareum, and Plexxikon, rather than
looking for a tight binding drug
lead, examine the weak interactions
of small fragments with a target and
expand on or connect individual
fragments to form a strongly bound
new drug candidate. This approach
requires knowledge of the three-
dimensional structure of both thetarget and the target-fragment com-
plex. This is usually determined by
X-ray diffraction. Data on the inter-
actions is often further verified by
other tools such as NMR. However,
researchers using this approach
may be stymied by proteins or small
molecule-protein complexes that
resist crystallization, and, even with
automated equipment, protein crys-
tallization remains more of an art
than a systematic technique.
Armed with preliminary structural
information showing the basis for
the fragment-protein interaction,
promising fragments are expanded
by chemists to fit the local protein
environment in an iterative process,
until a tight binding drug candidate
is developed. It is a logical method,
and the drug designer can easily fol-
low Lipinski’s Rule of Five, an empir-
ical rule of thumb delineating prop-
erties that maximize an oral drug
candidate’s probability of surviving
development [1], to narrow the uni-
verse of possibilities. According to
Lipinski, a molecule has a greater
chance of being orally active if it
has no more than 5 hydrogen bond
donors, not more than 10 hydrogen
bond acceptors, a molecular weight
under 500, and a LogP (a measure of
the molecule’s hydrophilicity) under
5. Advocates claim that FBDD is
faster than high throughput screen-
ing at identifying promising lead
candidates.
Structured around Structure
Dr. Harren Jhoti, chief scientific offi-
cer of Astex Therapeutics, devel-
oped his own corollary to Lipinski’s
rule. ‘‘In a nutshell, the idea here is,
rather than screening drug sized
molecules, which are between 300
and 500 molecular weight, in a kind
of bioassay-based high throughput
screen, one would look to screen li-
braries of fragments which are 100–
200 molecular weight,’’ said Jhoti.
‘‘Once you are able to visualize
how these fragments are bound to
your protein structure.it is really
the iterative optimizing of weak
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build that fragment up by adding
functional groups which improve
the potency but also the selectivity
of that compound for that target
and ensuring that it stays within the
appropriate space of drug-like fea-
tures.’’ Jhoti recalls that, with the ex-
ception of Abbott, big pharma com-
panies were initially skeptical. ‘‘We
may as well have been talking
Klingon,’’ Jhoti said. The fragment-
based discovery methodology As-
tex dubbed ‘‘Pyramid’’ soon proved
itself. ‘‘It is very chemistry efficient,’’
said Jhoti. ‘‘That is something indus-
try has always struggled with. The
amount of attrition [of early stage
leads] is huge.’’
Jhoti, formerly head of UK-based
structural drug design and bioinfor-
matics at Glaxo Wellcome, started
Astex Therapeutics in 1999 with Pro-
fessors Sir Tom Blundell and Chris
Abell, both structural biologists at
Cambridge University. Astex gar-
nered $90 million in two rounds of
financing from venture capitalists
including Abingworth, Advent Inter-
national, Alta Partners, Apax, GIMV,
HypoVereinsbank, Oxford Biosci-
ence Partners, Schering AG, and
the University of Cambridge.
According to Jeremy Carmichael,
Ph.D., Astex director of business de-
velopment, the company’s ratio of
approximately one structural biolo-
gist to two medicinal chemists allows
Astex to develop initial hits into leads
much faster than other companies.
Carmichael asserted that Astex
can produce 200–300 protein-ligand
structures a month, an order of mag-
nitude greater than the throughput of
most big pharma companies.
Astex Therapeutics has four can-
cer drug candidates in the pipeline.
‘‘We think we are the first biotech to
put a compound into man which
was based on a fragment hit,’’ said
Jhoti. ‘‘We went from first synthesis
of AT7519 to first dosing in patients
in 18 months. That is at least twice
as fast as industry standards.’’ Astex
has two other product candidates,
including AT9283, an aurora kinase
inhibitor that impedes mitosis (cell
division). AT9283 received FDA
Investigational New Drug (IND) ap-
proval in April 2006 and is now in
Phase I study in the U.S. AT9311, an
oral cell cycle inhibitor, is in preclini-
cal development with an IND/CTA
planned for the second half of 2006.Additionally, AT13387, an Hsp90
inhibitor, just entered preclinical
development.
Astex Therapeutics has drug dis-
covery and development alliances
with several large pharma compa-
nies potentially valued in excess of
US $1 billion, including a US $520
million alliance signed with Novartis
in 2005 to develop AT9311 and
AT7519. AstraZeneca is also working
with Astex Therapeutics to develop
small molecule inhibitors of the anti-
cancer target Protein Kinase B (also
known as Akt), a $5 million agree-
ment, following prior collaborations.
Puny Fragments Build Strong
Drugs
Sunesis Pharmaceuticals (www.
sunesis.com), a 130 person com-
pany located in South San Francisco,
focuses on cell-cycle inhibitors for
cancer. Sunesis calls its fragment-
based discovery approach ‘‘tether-
ing’’ and is focusing on weak binding
fragments by looking at the binding
event itself. Sunesis also uses an-
other approach called extended
tethering, where fragments are
linked by a covalent bond to the
target protein. ‘‘In one instance you
fish off the bank and the next you
fish off the pier,’’ said Dr. James
Wells, professor of pharmaceutical
chemistry and cellular and molecular
pharmacology at UCSF and Sunesis
cofounder.
Sunesis has three compounds in
the pipeline; SNS-595, in phase II
clinical trials; SNS-032, in phase I
clinical trials; and SNS-314 (preclini-
cal.) The company also has five stra-
tegic collaborations with Biogen
Idec, Johnson & Johnson PRD, and
Merck. Founded in 1998, Sunesis
raised $200 million from various in-
vestors and went public in 2005.
‘‘I think it [fragment based discov-
ery] is complementary to high-
throughput screening,’’ said Robert
McDowell, Ph.D, vice president, Dis-
covery Chemistry.
On the other side of the Bay, Plex-
xikon (www.plexxikon.com) is a 65
person company located in Berke-
ley. Plexxikon starts with fragments
between 150 and 350 Da in molecular
weight, then screens them using bio-
chemical assays, looking for very
weak activity. Subsequent cocrystal-
lographic structural analysis sorts
the wheat from the chaff. Some-
times, to get additional interactioninformation, Plexxikon employs di-
verse techniques like surface plas-
mon-enhanced Raman spectros-
copy and NMR to weed out the
false positives from each technique.
‘‘You use an assay just to identify
a measure of biochemical activity at
high concentration,’’ said Dean Artis,
‘‘We really let the crystals decide
what is an interesting compound
versus a confusing assay artifact.
You get a very small, compact
starting point.’’
Following this methodology, the
company develops a ‘‘scaffold’’
that has binding affinity for multiple
members of a protein family. Cur-
rently, Plexxikon uses several scaf-
folds to target each of three protein
families (kinases, nuclear receptors,
phosphodiesterases). Artis com-
mented that Plexxikon has filed
INDs for molecules generated using
this approach. According to Artis,
candidate compounds for preclini-
cal testing can be generated in as
little as 3–6 months. The company
initiated collaborations with Genen-
tech, Inc., in 2003 and Wyeth Phar-
maceuticals in 2004.
‘‘I came to Plexxikon to make
drugs,’’ Artis said. ‘‘This process
gives you a very efficient path to do
not just an exercise in technology,
but to do drug design in a time frame
that might actually help people
sooner rather than later. Our first drug
is in patients, and we’ve only been
doing chemistry for four years.’’
What is the view of big pharma on
this method? ‘‘We typically use it
as the complementary method to
HTS,’’ said Dr. Andreas Marzinzik,
group leader, Integrated Lead Dis-
covery Program, Novartis Institute
of Biomedical Research, ‘‘we would
really want to focus on targets where
HTS delivers no promising hits.’’
Marzinzik cited, for example, non-
ATP competitive inhibitors of ki-
nases, which are hard to identify by
high throughput screening. ‘‘The ad-
vantage is really that FBS technology
is not prone to false positives.’’
According to Marzinzik, Novartis
assembled a working group to ad-
vance fragment-based discovery
technology in 2005. Novartis has an
internal project and also collaborates
with outside companies for specific
projects. ‘‘It is definitely a tool for us
here at Novartis,’’ Marzinzik said.
It remains an open question, after
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801leads, if FBDD really shaves off that
much time and effort from the dis-
covery process. But it could pick up
a few unprepossessing fragments
that might grow up to be great drugs
if they just got a bit of attention.
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